Market News & Trends
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
BioXcel Therapeutics, Inc. recently announced promising top-line data from its Phase 2 trial of BXCL701, the company's investigational, oral innate immune activator, in combination with…
Sterling Pharma Solutions Completes Acquisition of API Manufacturing Facility in Ireland
Sterling Pharma Solutions recently announced the completion of its acquisition of an active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, from Novartis, in a…
Ajinomoto & Exelixis Enter License Agreement to Discover & Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Ajinomoto Co., Inc. recently announced a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of….
CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide
CordenPharma recently announced the signing of a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.…
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for Novel Immunotherapeutic for Type 1 Diabetes
SAB Biotherapeutics recently announced the successful completion of an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic as a way to prevent and/or delay onset…
Absci First to Create & Validate De Novo Antibodies With Zero-Shot Generative AI
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic….
Atavistik Bio Announces Collaboration With Plex Research to Enrich the Informatics Capabilities of its AMPS Platform & Accelerate the Discovery of Novel Small Molecule Therapeutics
Atavistik Bio recently announced it has entered into a collaboration agreement with Plex Research, a company providing a novel artificial intelligence (AI)-powered drug discovery platform.…
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Vaccinex, Inc. recently announced its licensee, Surface Oncology dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s…
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients With Heart Failure With Preserved Ejection Fraction
Imbria Pharmaceuticals, Inc. recently announced the enrollment of the first patient in Part 2 of the IMPROVE-DiCE Phase 2 clinical trial of ninerafaxstat in patients…
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
Derm-Biome Pharmaceuticals, Inc. recently announced that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego (UCSD)…
Centogene & Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Centogene N.V. recently announced it has extended the Rostock International Parkinson's Disease (ROPAD) Study to recruit and genetically test additional patients over the next few…
Celltrion & Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
Rani Therapeutics Holdings, Inc. recently announced it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar….
Transgene Receives Approval to Start a Phase 1 Trial of Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recently announced it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase 1 clinical trial of TG6050, a novel oncolytic….
Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy for the Treatment of Leber Congenital Amaurosis-2
Frontera Therapeutics recently announced it has dosed the first patient in a Phase 1 clinical trial of its lead gene therapy program, FT-001, for the…
Sarepta & Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Catalent, Inc. and Sarepta Therapeutics, Inc. recently announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced…
SAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-Idiotype Antibodies to Help Treat Autoimmune Diseases
SAB Biotherapeutics recently announced results from a project in collaboration with global biotechnology leader CSL confirming that SAB’s DiversitAb platform can generate functional fully human anti-idiotype polyclonal….
Paratek Pharmaceuticals Receives $36.4-Million Milestone Payment Associated With the Second Procurement of NUZYRA Under BARDA Project BioShield Contract
Paratek Pharmaceuticals, Inc. recently announced the receipt of a $36.4-million milestone payment associated with the second procurement of NUZYRA (omadacycline) under the company’s Project BioShield…
Ovid Therapeutics Dosed Healthy Volunteers With OV329 in Phase 1 Trial
Ovid Therapeutics Inc. recently dosed healthy volunteers with OV329 in late December 2022, as part of a Phase 1 study. The company is conducting the…
IMUNON Enters Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
IMUNON, Inc. and The Wistar Institute recently announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the….
Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Preclinical Trial
Clearmind Medicine Inc. recently announced positive preclinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at…
